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Abstract
Purpose: In advanced radiotherapy techniques such as intensity-modulated radiation therapy
(IMRT), the quality assurance (QA) process is essential. The aim of the study was to assure
the treatment planning dose delivered during delivery of complex treatment plans. The QA
standard is to perform patient-specific comparisons between planned doses and doses
measured in a phantom. Materials and method: The Delta 4 phantom (Scandidos, Uppsala,
Sweden) has been used in this study. This device consists of diode matrices in two orthogonal
planes inserted in a cylindrical acrylic phantom. Each diode is sampled per beam pulse so that
the dose distribution can be evaluated on segment-by-segment, beam-by-beam, or as a
composite plan from a single set of measurements. Ninety-five simple and complex
radiotherapy treatment plans for different pathologies, planned using a treatment planning
system (TPS) were delivered to the QA device. The planned and measured dose distributions
were then compared and analysed. The gamma index was determined for different
pathologies. Results: The evaluation was performed in terms of dose deviation, distance to
agreement and gamma index passing rate. The measurements were in excellent agreement
between with the calculated dose of the TPS and the QA device. Overall, good agreement was
observed between measured and calculated doses in most cases with gamma values above 1 in
>95% of measured points. Plan results for each test met the recommended dose goals.
Conclusion: The delivery of IMRT and volumetric-modulated arc therapy (VMAT) plans was
verified to correspond well with calculated dose distributions for different pathologies. We
found the Delta 4 device is accurate and reproducible. Although Delta4 appears to be a
straightforward device for measuring dose and allows measure in real-time dosimetry QA, it
is a complex device and careful quality control is required before its use.
Introduction
Modern radiotherapy is a complex procedure that involves the delivery of complex intensity
patterns of photon beams from various gantry angles. Intensity-modulated radiation therapy
(IMRT) is an advanced radiotherapy technique that allows the radiation dose to precisely
conform to the shape of complex tumours while minimising the dose to the surrounding
normal tissue. A single plan can consist of more than a 100 control points and include multi-
leaf collimator (MLC) leaf movements, gantry and collimator angle rotations and so on in
order to produce steep dose gradients within the patient. Currently, the use of IMRT is focused
on conformal avoidance of organs at risk (OAR) or dose escalation strategies to the planning
target volume aimed at increasing tumour control. Because of the complex nature of treatment
planning and delivery of IMRT, a stringent quality assurance (QA) program has been
recommended for its safe and effective implementation in clinical practice.1
This requires a constant evolution of QA methods used to verify the performance of the
systems.Of course, different types of systemshave differentQAneeds. For example, the following
types of X-ray radiation therapy delivery systems are different enough from each other that they
demand unique QA strategies: static gantry intensity-modulation radiation therapy (IMRT),
helical tomotherapy, volumetric-modulated arc therapy (VMAT) and robotic arm therapy.
A patient-specific QA process is often performed in order to ensure the accuracy of the
delivered absorbed dose distribution during IMRT treatment. The QA is most often based on
measurements of delivered dose to find possible deviations between the planned and the
delivered dose distribution. The method used for patient-specific IMRT QA measurements
depends on the equipment available at the clinic, but the result of the QA is also dependent on
the evaluation procedure, for example, the choice of acceptance criteria and tolerance levels.
The QA could be designed to have different intentions, either to reveal major errors, such as
no MLC in the beam or use of the wrong plan, but it could also be designed to find smaller
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deviations between planned and delivered dose. It is important to
understand what the combination of dosimetry system and
valuation procedure implies in terms of what kind of deviations
and/or errors will be detected.
When modern techniques, such as IMRT and VMAT, are
introduced into clinical practice, extensive dosimetric QA is
required to ensure accurate treatment delivery. This QA
encompasses both general machine performance and QA at the
patient-specific level. In our busy department, we are treating
VMAT and IMRT for various body sites: prostate, lung, head and
neck and breast cancer. For each patient, measurements are
performed using the Delta4 phantom for the preclinical testing.
Due to the unique and patented design of Delta4 phantom
(Scandidos, Uppsala, Sweden) with a cylindrical, water equivalent,
phantom and a high number of detectors in fixed positions in the
isocentric tumour and high-gradient region, it can directly verify
the delivered dose and compare this with the plan without any
additional processing software.
In this study, we measure and analysed the dose distribution of
different IMRT, VMAT and three-dimensional conventional
radiotherapy (3D CRT) plans with the intent to provide pre-
treatment patient-specific QA.
Materials and Method
All measurements were carried out at University Hospital Ghent.
Ninety-five patients were randomly selected in this study,
IMRT-30 cases, VMAT-40 cases, Stereotatic Body Radiation
Therapy-20 cases and 3D CRT-5 cases. The experiments were
performed using a linear accelerator equipped with a 120-leaf
millennium MLC (Varian Medical Systems, Palo Alto, CA) with
the record and verify system ARIA. Two Synergy linear accel-
erators equipped with a conventional MLC, model MLCi2, of
1 cm leaf width (Elekta, Inc. Crawley, UK) with Mosaiq (a certi-
fied electronic medical record and practice management system).
The treatment plans were generated using Eclipse 8.5 (Varian)
and RayStation® v6 treatment planning system (TPS) (RaySearch
Medical Laboratories, Stockholm, Sweden) respectively.
The Delta4 phantom monitors with high accuracy, the dose
that is delivered to the patient. It automatically compares the
delivered dose with the planned dose, ensuring that the treatment
is delivered precisely and safely.
The Delta4 is a cylindrical phantom made of polymethyl-
methacrylate (PMMA) with the dimensions of 22 cm in diameter
and a length of 40 cm (Figure 1). There are two detector planes
crossing each other at the center line that generally contains the
treatment isocenter point. Although the system has detectors in
only two planes, it features a unique interpolation algorithm that
is capable of estimating doses at points where no detectors are
present.
The planar main detector board divides the entire phantom
into two halves, while the two wing detector boards are within the
second plane but separated allowing the main detector board to
pass through the centre line of the phantom.
The boards are angled at +50° from the vertical for the main
board and −40° for the wings. This allows for added flexibility to
make sure the beam is not parallel to the boards. The two detector
planes consist of 1069 p-type Silicon diodes. Each diode is sampled
per dose pulse so that the dose distribution can be evaluated on
segment-by-segment, beam-by-beam, or as a composite plan from
a single set of measurements. The detection area per plane is
20×20cm2, and the diodes are placed with a spacing of 0·5 cm in the
central area (6×6cm2) and a spacing of 1 cm in the outer area. The
maximum deviation of the detector positions is 0·5mm. The lowest
dose that can be measured is 1 mGy and the resolution is 0·01 mGy.2
The device records measured dose in relation to the individual
accelerator pulses by using a trigger signal from the accelerator.
After the radiation oncologist had accepted the patient treat-
ment plan, it was transferred within the TPS to the CT scan of the
Delta4 phantom in order to calculate the dose in the phantom.
The recalculating dose distribution, the planning data, such as the
beam arrangement, and structures from the original plan were
transferred to the Delta4 system as Digital Imaging and Com-
munication in Medicine, Radiation Therapy objects. The software
has a variety of tools for displaying and analysing the difference
between the measured and the calculated dose.
The agreement between calculated and measured dose dis-
tributions was analysed. The most important used parameters are
dose agreement (DA) and distance to agreement (DTA). DA is
the percentage or absolute difference between measured and
calculated dose. It is not suitable for the high-dose gradient
region, where even small spatial errors may lead to large but not
significant errors. Therefore, DTA is used in high-dose gradient
region. It is defined as the minimum distance, in the plane,
between a measured point and the nearest point in the calculated
dose distribution that has the same dose. It is important to
indicate that DTA measurement depends on the choice of
the correct common coordinate system between measured and
calculated dose. The results depend on the choice of DTA.
The gamma analysis (γ) was performed based on the formulae
by Low et al.3,4 The histograms of dose deviation (DD), DTA,
gamma index and the passing rates were calculated by the
Delta4’s software. The acceptance criteria used in our department
are 3% dose difference and 3mm DTA and the γ-index passing
rate is 95% and 90% for IMRT and VMAT, respectively. The Delta4
Figure 1. Delta4 phantom set up at isocenter in measurement position.
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has the ability to measure and evaluate each field individually and
also the total plan. In our Radiation Therapy department, 30 patients
with different pathologies, were controlled for IMRT and VMAT by
using the Delta4 phantom per week. The correction factor of Delta4
phantom was measured in box field technique (gantry angles of 0°,
90°, 180° and 270°) for a 10×10 cm2 field size, daily. The correction
factor is recommended by vendor due to correction of temperature
of Delta4 phantom in the storing place. The factor was applied to
each patient plan.
Results
All plans were analysed using the three parameters, the %DA
(limit 3%), DTA (limit 3mm), and γ-pass rate with the 3% dose
tolerance and 3mm DTA in relation to the TPS. Table 1 summarises
the results of average γ-passing rate, dose deviation and DTA of
different pathologies in our center. Overall, good agreement was
observed between measured and calculated doses in most cases. The
gamma pass rate percentages over all plans were higher than
≤97·1% using 3% DD and 3mm DTA. It should be noted that for
all plans, our clinical standard of 90% or greater for the gamma
index percentage was achieved. Myers et al.5 reported a similar result
as well. Bedford et al.6 reported that, from the gamma values, Delta4
shows slightly better agreement between measured and calculated
doses than the film in a cuboid phantom. The reason could be the
fact that the Delta4 measurements are absolute, whereas film is used
as a relative dosimeter.
Figure 2 shows an example of measurements on a nasopharynx
case. The treatment plan consists of seven beam IMRT. The daily
correction factor was applied. The planned dose distribution was in
greyscale and the measured dose in colour over the main and wing
detector boards. The software shows the matrix of γ statistics points
(blue pass (γ< 1) and red fail (γ> 1)).
Table 1. Average γ-passing rate, dose deviation and distance to agreement of different pathologies. Indicated statistical error uncertainty is standard deviation
Pathologies
Plan analysing Prostate Cervix Breast Lung Liver Esophagus Head and neck
Average % γ-passing rate 99·0 ± 1·01 98·5 ± 1·01 97·7 ± 1·45 97·1 ± 1·23 97·6 ± 1·25 97·8 ± 1·52 98·5 ± 1·30
Average DD 75·8 ± 8·2 90·4 ± 3·4 86·2 ± 6·9 65·8 ± 8·7 89·7 ± 9·7 62·2 ± 7·1 82·8 ± 5·2
Average DTA 94·1 ± 2·2 96·7 ± 4·7 94·5 ± 5·4 90·1 ± 8·9 96·3 ± 2·8 98·7 ± 4·1 97·4 ± 5·2
Figure 2. A screenshot from the Delta4 software showing the result of seven beams intensity-modulated radiation therapy (IMRT) delivery for a nasopharynx case. The upper
panel shows the absolute dose measured in two diode arrays in 3D with color coding denoting the dose. The lower panel shows three histograms: dose deviation from the
planned dose, distance to agreement from the planned dose and gamma index distribution.
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Figure 3 shows the total absolute dose difference between
planned and measured dose in X- and Y-axis of detector plane in
nasopharynx case. The software can also analyse absolute and
relative dose difference in beam per beam.
The daily correction factor was found to be 1·02± 0·0056 (SD).
The temperature dependence of the diodes is another potential source
of uncertainty.7 It has shown it to be very small (i.e., 0·4%/°C). Several
basic tests (linearity of segmental dose, angular sensitivity, dose rate)
were carried out to examine specific performance characteristics of
the Delta4 phantom. These results have not been presented here.
Delta4 phantom is also fully recalibrated once a year.
In practice, if portal dosimetry (PD) fails, which means that the plan
has not passed the gamma criteria passing rate (3%, 3mm), the patient
plan is then re-measured by using the Delta 4 phantom. The same plan
has passed the gamma criteria using the Delta 4 phantom. The limited
size of the detector panel of the linear accelerator is a major reason for
PD failure. Other patient-specific reasons for PD failure were not fur-
ther investigated. Daci and Malkaj8 studied Delta4 phantom and PD as
dosimetry verification tools for IMRT and VMAT. They conclude that
Delta4 was more accurate in measurements, however, the electronic
portal imaging device is more time efficient.
Discussion
The Delta4 phantom can be set-up easily, and positional errors
can be reduced to the minimum. It is important that the initial
calibration and the commissioning process of Delta4 are
accomplished with rigorous and careful measurements to ensure
that patient-specific QA tests are accurate. It provides a thorough
data analysis and a relatively faster way to take measurements
without necessitating further QA systems. Measurements take
place on the two planes of the phantom, where a 3D dose dis-
tribution of the dose can be computed by the software of the
phantom through an interpolation method.
According to the study by Nelms et al.,9 a field-by-field eva-
luation is unsuitable for IMRT. Their study showed that gamma
passing rates with the criteria of (3%, 3mm) are not sensitive to
clinically relevant patient dose errors on a field by field basis,
which is confirmed by our study as well. Sadagopan et al.10 also
confirmed that the Delta4 device is accurate and reproducible in
comparing to an ion chamber and film.
For a VMAT plan, where roughly 33% of the arc intersects
with the couch, the effect of the couch should be modelled in the
TPS, although the dosimetric effect of this is often not a
straightforward process on a routine basis. Our previous study11
suggests that the tabletop modeling results are in better agreement
between measurements and calculations, both for total plans and
individual beams. This agreement further improves when proper
correction factors are applied.
Nilsson et al.12 investigated dose distributions passing the
gamma evaluation (5%, 5mm) according to the recommendation
of the International Commission on Radiation Units and Mea-
surements report 8313 with the use of the Delta4 dosimetry system.
Figure 3. A screenshot from the Delta4 software showing seven beams intensity-modulated radiation therapy (IMRT) delivery. The upper panel shows the absolute dose
difference in two diode arrays in 2D with color coding denoting the dose. The lower panel shows two graphs: dose profiles along X- and Y-axis.
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We also confirmed the passing gamma criteria (3%, 3mm).
Chandraraj et al.14 used four commercial devices [PTW 2D-ARRAY
seven29 (PTW Freiburg GmbH, Germany), IBA I’MatriXX (IBA
dosimetry, GmbH, Schwarzenbruck, Germany), EDR2 film (Kodak,
Rochester, NY) and Delta4 phantom)] and concluded that Delta4
measurements met the gamma criteria in all pathologies.
The Delta4 phantom consists of two orthogonal detector
planes located at a specific position inside the cylindrical phan-
tom. The detector points are located on these two planes and the
absorbed dose can only be determined in these points. The spinal
cord is located in the dorsal region, and the parotid glands are
located in the left and right periphery. These positions are not
covered by any detector points in the phantom. The OAR is
thereby located between the detector planes. It seems that these
organs are not able to be measured by existing software in our
department. Delta4DVH software module only allows comparison
in patient anatomy of the planned and the delivered patient dose.
The real dose deviation in each organ is evaluated by Delta4DVH
software. The software immediately determines if the dose to an
organ at risk is too high or not.
Conclusion
The Delta4 software and phantom system offer a fast set-up,
measurement control and three-dimensional analysis that are
highly adapted to the complexities of modulated irradiation. The
results indicate that Delta4 phantom is an effective and efficient
method for patient-specific QA. Delta4 phantom has proven to be
fast and reliable for patient-specific QA of the VMAT, step-and-
shoot IMRT and 3D CRT. Patient-specific QA using Delta4
phantom has not been compared against another QA verification
system due to the pressures of time and other QA systems are not
available in the department at the present time. The work could
be further extended in the future.
Acknowledgement. None.
References
1. Palta JR, Liu C, Li J G. Quality assurance of intensity-modulated radiation
therapy. Int J Radiat Oncol 2008; 71 (Suppl 1): S108–S112.
2. Scandidos. Delta4PT User’s Guide. Uppsala, Sweden: Scandidos, 2013.
3. Low D A, Harms W B, Mutic S, Purdy J A. A technique for the
quantitative evaluation of dose distributions. Med Phys 1998; 25 (5):
656–661.
4. Low D A. Gamma dose distribution evaluation tool. J Phys Conf Series
2010; 250 (012071), 1–11.
5. Myers P, Stathakis S, Gutiérrez A, Esquivel C, Mavroidis P, Papanikolaou
N. Evaluation of PTW Seven29 for tomotherapy patient-specific quality
assurance and comparison with ScandiDos Delta4. J Med Phys Assoc Med
Phys India 2012; 37 (2): 72.
6. Bedford J, Lee Y, Wai P, South C, Warrington A P. Evaluation of the
Delta4 phantom for IMRT and VMAT verification. Phys Med Biol 2009;
54 (9): N167–N176.
7. Nilsson G. Delta4—a new IMRT QA device. Med Phys 2007; 34 (6):
2432–2432.
8. Daci L, Malkaj P. Implementation of IMRT and VMAT using Delta4
phantom and portal dosimetry as dosimetry verification tools. AIP Conf
Proc 2016; 1722 (1): 030002.
9. Nelms B, Zhen H, Tomé W A. Per-beam, planar IMRT QA passing rates
do not predict clinically relevant patient dose errors. Med Phys 2011; 38
(2): 1037–1044.
10. Sadagopan R, Bencomo J, Martin R, Nilsson G, Matzen T,
Balter P A. Characterization and clinical evaluation of a novel IMRT
quality assurance system. J Appl Clin Med Phys 2009; 10 (2): 104–119.
11. Paelinck L, Vanderstraeten B, Srivastava R, Olteanu L, De Wagter C. The
effect of the table top modeling on calculations and measurements for the
Delta4 phantom. ESTRO 2016; 35: S705–S706.
12. Nilsson J, Hauer A, Bäck A. IMRT patient-specific QA using the Delta4
dosimetry system and evaluation based on ICRU 83 recommendations.
J Phys Conf Series 2013; 444 (012048), 1–4.
13. Prescribing, recording, and reporting photon-beam intensity-modulated
radiation therapy (IMRT): contents. J ICRU 2010; 10 (1), NP.3-NP.
14. Chandraraj V, Stathakis S, Manickam R, Esquivel C, Supe S,
Papanikolaou N. Comparison of four commercial devices for RapidArc
and sliding window IMRT QA. J Appl Clin Med Phys 2011; 12 (2):
338–349.
214 R.P. Srivastava and C. De Wagter
© Cambridge University Press 2018 
